DexCom, Inc. (NASDAQ:DXCM) Shares Acquired by Kentucky Retirement Systems

Kentucky Retirement Systems increased its position in DexCom, Inc. (NASDAQ:DXCM) by 2.4% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 29,968 shares of the medical device company’s stock after acquiring an additional 691 shares during the period. Kentucky Retirement Systems’ holdings in DexCom were worth $3,398,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. Seven Eight Capital LP raised its position in shares of DexCom by 825.6% in the second quarter. Seven Eight Capital LP now owns 47,225 shares of the medical device company’s stock valued at $5,354,000 after buying an additional 42,123 shares during the last quarter. Amalgamated Bank raised its position in shares of DexCom by 1.1% in the second quarter. Amalgamated Bank now owns 84,778 shares of the medical device company’s stock valued at $9,612,000 after buying an additional 891 shares during the last quarter. Meiji Yasuda Asset Management Co Ltd. raised its position in shares of DexCom by 9.4% in the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 5,976 shares of the medical device company’s stock valued at $678,000 after buying an additional 512 shares during the last quarter. SYSTM Wealth Solutions LLC raised its position in shares of DexCom by 10.3% in the second quarter. SYSTM Wealth Solutions LLC now owns 25,201 shares of the medical device company’s stock valued at $2,857,000 after buying an additional 2,344 shares during the last quarter. Finally, E Fund Management Co. Ltd. raised its position in shares of DexCom by 6.5% in the second quarter. E Fund Management Co. Ltd. now owns 5,455 shares of the medical device company’s stock valued at $618,000 after buying an additional 331 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on DXCM shares. StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a research report on Monday, June 10th. Barclays dropped their price target on shares of DexCom from $138.00 to $113.00 and set an “equal weight” rating for the company in a research report on Monday, July 29th. Redburn Atlantic started coverage on shares of DexCom in a research report on Thursday, May 30th. They set a “neutral” rating and a $130.00 price target for the company. Stifel Nicolaus upped their price target on shares of DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, August 23rd. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $90.00 price target on shares of DexCom in a research report on Monday, August 26th. Seven investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, DexCom presently has an average rating of “Moderate Buy” and a consensus price target of $112.25.

Insider Activity

In other DexCom news, EVP Sadie Stern sold 426 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the transaction, the executive vice president now directly owns 75,451 shares in the company, valued at approximately $5,217,436.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other DexCom news, EVP Sadie Stern sold 426 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the transaction, the executive vice president now directly owns 75,451 shares in the company, valued at approximately $5,217,436.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Michael Jon Brown sold 652 shares of the stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total transaction of $45,346.60. Following the transaction, the executive vice president now owns 66,249 shares in the company, valued at $4,607,617.95. The disclosure for this sale can be found here. Over the last three months, insiders sold 2,483 shares of company stock worth $201,708. 0.30% of the stock is currently owned by company insiders.

DexCom Price Performance

Shares of DXCM stock opened at $71.92 on Friday. The company has a market capitalization of $28.60 billion, a PE ratio of 46.40, a price-to-earnings-growth ratio of 2.12 and a beta of 1.18. The firm has a fifty day simple moving average of $79.06 and a 200-day simple moving average of $109.99. The company has a current ratio of 2.82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.04. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The business’s quarterly revenue was up 15.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.34 earnings per share. Equities research analysts anticipate that DexCom, Inc. will post 1.69 earnings per share for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.